EGFR Overview
Molecule Name
Epidermal growth factor receptor erbB1
Synonyms
EGFR
Drug Development Progress
Drugs in Clinical Trials188
Approved Drugs34
Highest Development StageApproved
Target Synonym
Epidermal Growth Factor Receptor (Avian Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog)，Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog (Avian)，Avian Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog，Epidermal Growth Factor Receptor Tyrosine Kinase Domain，Cell Proliferation-Inducing Protein 61，Cell Growth Inhibiting Protein 40，EC 2.7.10.1，NISBD2，PIG61，MENA，EC:2.7.10.1，EC 2.7.10，Receptor tyrosine-protein kinase erbB-1，Proto-oncogene c-ErbB-1，Epidermal growth factor receptor，EGFR，Erb-B2 Receptor Tyrosine Kinase 1，ERBB1，ERBB，HER1
EGFR Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| PLB-1004 | PLB-1004 | Phase 3 Clinical | Beijing Avistone Pharmaceuticals Biotechnology Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| YK-029A | YK-029A; YK-209A; YK-209-A; YK-029-A | Phase 3 Clinical | Hainan Yuekang Biomedicine Co Ltd | Drug-Related Side Effects and Adverse Reactions; Carcinoma, Non-Small-Cell Lung | Details |
| Petosemtamab | MCLA-158 | Phase 3 Clinical | Merus Nv | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Olafertinib | CK-101; RX-518; CS-2481; EGFR-IN-3 | Phase 3 Clinical | Suzhou Neupharma Co Ltd | Lung Diseases; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
| Cetuximab biosimilar (AlphaMab) | KN-005 | Phase 3 Clinical | Suzhou Alphamab Co Ltd | Head and Neck Neoplasms; Anus Neoplasms; Urinary Bladder Neoplasms; Colorectal Neoplasms | Details |
| HA121-28 | HA121-28; SYHA121-28 | Phase 3 Clinical | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd | Biliary Tract Neoplasms; Solid tumours; Esophageal Neoplasms; Neoplasms; Medullary thyroid cancer (MTC); Bile Duct Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Nimotuzumab biosimilar (El Kendi Pharmaceuticals Manufacturing) | Phase 3 Clinical | El Kendi Pharmaceuticals | Uterine Cervical Neoplasms | Details | |
| Cetuximab biosimilar (AMPO Biotechnology) | Phase 3 Clinical | Ampo Biotechnology Inc | Colorectal Neoplasms | Details | |
| Cetuximab biosimilar (R-Pharm) | RPH-002 | Phase 3 Clinical | R-Pharm | Head and Neck Neoplasms; Pancreatic Neoplasms | Details |
| QL1203 | QL-1203 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Colorectal Neoplasms | Details |
| BEBT-109 | BEBT-109 | Phase 3 Clinical | Guangzhou BeBetter Medicine Technology Co | Carcinoma, Non-Small-Cell Lung | Details |
| Immunomodulatory progenitor cell therapy (Celixir) | Phase 3 Clinical | Celixir | Endomyocardial Fibrosis; Cardiomyopathies | Details | |
| Izalontamab | SI-B001; SI-1X6.4 | Phase 3 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Head and Neck Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Neoplasms, Glandular and Epithelial; Triple Negative Breast Neoplasms; Digestive System Neoplasms; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung | Details |
| Ruserontinib | SKLB-1028 | Phase 3 Clinical | Sichuan University, CSPC Pharmaceutical Group Ltd | Solid tumours; Leukemia, Promyelocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute | Details |
| Varlitinib Ditosylate | SPS-4370; ASLAN-001; ARRY-334543; ARRY-543; QBT-01 | Phase 3 Clinical | Array Biopharma | Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Cholangiocarcinoma; Bile Duct Neoplasms; Metastatic breast cancer | Details |
| Becotatug | JMT-101 | Phase 3 Clinical | Shanghai Jmt-Bio Inc | Solid tumours; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
| HS-20117 | HS-20117; PM1080; PM-1080 | Phase 3 Clinical | Biotheus Inc | Solid tumours; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| SYS-6010 | SYS-6010; CPO-301; CPO301; SYS6010 | Phase 3 Clinical | Jushi Biopharmaceutical Co Ltd | Solid tumours; Small Cell Lung Carcinoma; Neoplasms; Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| IAE-0972 | IAE-0972 | Phase 3 Clinical | SunHo (China) BioPharmaceutical Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Nasopharyngeal Carcinoma; Carcinoma, Hepatocellular; Neoplasm Metastasis | Details |
| BAY-2927088 | BAY-2927088; BAY2927088 | Phase 3 Clinical | Bayer AG, Broad Institute, Harvard University | Solid tumours; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
| Izalontamab brengitecan | BMS-986507; BL-B01D1 | Phase 3 Clinical | Sichuan Baili Pharmaceutical Co Ltd, SystImmune | Chordoma; Uterine Cervical Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Metastatic breast cancer; Colorectal Neoplasms; Urologic Neoplasms; Breast Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Digestive System Neoplasms; Carcinoma, Transitional Cell; Nasopharyngeal Neoplasms; Small Cell Lung Carcinoma; Glioblastoma; Triple Negative Breast Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms, Fibroepithelial | Details |
| Nimotuzumab biosimilar (IBC Generium) | Phase 3 Clinical | International Biotechnology Center Generium Llc | Head and Neck Neoplasms | Details | |
| Depatuxizumab mafodotin | ABT-414; ABT-414/806 | Phase 3 Clinical | Abbvie Inc | Glioblastoma; Gliosarcoma; Carcinoma, Squamous Cell; Glioma | Details |
| EG-007 | EG-007 | Phase 3 Clinical | Shenzhen Aigelin Pharmaceutical Co Ltd | Endometrial Neoplasms | Details |
| Larotinib Mesylate | Z-650 | Phase 3 Clinical | Guangdong Dongyangguang Pharmaceutical Co Ltd | Solid tumours; Esophageal Neoplasms; Pancreatic Neoplasms; Esophageal Squamous Cell Carcinoma | Details |
| Ametumumab | SY-101 | Phase 2 Clinical | Institute of Bioengineering Academy of Military Medical Sciences Chinese People's Liberation Army, Shanghai Serum Bio-Technology Co Ltd | Solid tumours; Colorectal Neoplasms | Details |
| BB-401 | BB-401 | Phase 2 Clinical | Benitec Biopharma Ltd | Squamous Cell Carcinoma of Head and Neck | Details |
| Sutetinib Maleate | Phase 2 Clinical | Jiangsu Maidu Pharmaceutical R & D Co Ltd, Jiangsu Suzhong Pharma Group Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details | |
| GC-1118A | GC-1118; GC-1118A | Phase 2 Clinical | GC Biopharma Corp | Solid tumours; Stomach Neoplasms; Colorectal Neoplasms; Neoplasm Metastasis | Details |
| Durvalumab/Gefitinib | Phase 2 Clinical | Medimmune | Carcinoma, Non-Small-Cell Lung | Details | |
| Pamvatamig | MCLA-129 | Phase 2 Clinical | Merus Nv | Solid tumours; Head and Neck Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
| JNJ-26483327 | JNJ-26483327; MTKi-327; BGB-102 | Phase 2 Clinical | Johnson & Johnson | Solid tumours; Neoplasms; Macular Degeneration | Details |
| HER-1 vaccine (Center of Molecular Immunology) | HER1-ECD; HER1-VSSP; HER-1-ECD-VSSP | Phase 2 Clinical | Center Of Molecular Immunology | Neoplasms | Details |
| WSD-0922 | WSD0922; WSD-0922 | Phase 2 Clinical | Wayshine Biopharm International Ltd | Glioblastoma; Neoplasms; Astrocytoma; Carcinoma, Non-Small-Cell Lung | Details |
| AFM-24 | AFM-24 | Phase 2 Clinical | Affimed | Solid tumours | Details |
| C225-ILS-DOX | C225-ILs-dox | Phase 2 Clinical | Universitaetsspitals Basel | Breast Neoplasms | Details |
| Nazartinib | EGF-816; EGFRmut-TKI EGF816 | Phase 2 Clinical | Novartis Pharma Ag | Bronchial Neoplasms; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
| Sapitinib | AZD-8931 | Phase 2 Clinical | Astrazeneca Plc | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Metastatic breast cancer; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
| Tesevatinib | XL-647; KD-020; KD-019; EXEL-7647 | Phase 2 Clinical | Exelixis Inc | Neoplasms; Glioblastoma; Breast Neoplasms; Brain Neoplasms; Polycystic Kidney, Autosomal Dominant; Brain metastases; Neoplasm Metastasis; Polycystic Kidney, Autosomal Recessive; Carcinoma, Non-Small-Cell Lung | Details |
| Futuximab/Modotuximab | Sym-004; S95026; S-95026; 992-and-1024 | Phase 2 Clinical | Symphogen A/S | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Colorectal Neoplasms; Glioma | Details |
| BB-101 (Blue Blood Biotech/National Cheng Kung University) | BB-101 | Phase 2 Clinical | National Cheng Kung University, Blue Blood Biotech Corp | Diabetic Foot | Details |
| DBPR-112 | ABT-101; DBPR-112 | Phase 2 Clinical | National Health Research Institutes | Solid tumours; Head and Neck Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Panitumumab-IRDye800CW (Stanford University) | Phase 2 Clinical | Stanford University | Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Brain Neoplasms | Details | |
| AMX-3009 Maleate | AMX-3009; AMX3009马来酸 | Phase 2 Clinical | Anrun Medicine Technology (Suzhou) Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
| Allitinib Tosylate | AST-6; ALS-1306; AST-1306 | Phase 2 Clinical | Shanghai Allist Pharmaceutical Technology Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Demupitamab | SCT-200 | Phase 2 Clinical | SinoCelltech Ltd | Head and Neck Neoplasms; Solid tumours; Biliary Tract Neoplasms; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Neoplasms; Colorectal Neoplasms; Gallbladder Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
| Cetuximab-IRDye800CW (University Medical Center Groningen) | Phase 2 Clinical | Umcg The University Medical Center Groningen | Rectal Neoplasms; Penile Neoplasms; Lung Neoplasms | Details | |
| Selatinib Ditosilate | QLNC-120 | Phase 2 Clinical | Qilu Antibiotics (Linyi) Pharmaceutical Co Ltd, Qilu Pharmaceutical Co Ltd | Breast Neoplasms | Details |
| Pimurutamab | HLX-07 | Phase 2 Clinical | Shanghai Henlius Biotech Inc | Solid tumours; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Rectal Neoplasms; Esophageal Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Basosquamous; Carcinoma, Adenosquamous; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| NRC-2694 | NRC-2694; NRC-2694A; NRC-2694-A | Phase 2 Clinical | Natco Pharma | Carcinoma; Squamous Cell Carcinoma of Head and Neck | Details |
| Bafisontamab | FIT-013a; EMB-01 | Phase 2 Clinical | Shanghai Epimab Biotherapeutics, Inc | Biliary Tract Neoplasms; Liver Neoplasms; Stomach Neoplasms; Neoplasms; Digestive System Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Gastrointestinal Neoplasms | Details |
| Recombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian) | CPGJ-602; 602; CPGJ602; CPGJ 602 | Phase 2 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Colorectal Neoplasms | Details |
| GB-263 | GB-263; GB-263T | Phase 2 Clinical | Genor Biopharma Co Ltd | Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| ORIC-114 | ORIC-114; VRN-07 | Phase 2 Clinical | Voronoi Inc | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
| WJ-13404 | WJ-13404; JS-113; WJ-004 | Phase 2 Clinical | Wigen Biomedicine technology (Shanghai) Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| BDTX-1535 | BDTX-1535 | Phase 2 Clinical | Black Diamond Therapeutics Inc | Glioblastoma; Glioma; Carcinoma, Non-Small-Cell Lung | Details |
| BH-30643 | BH-30643 | Phase 2 Clinical | BlossomHill Therapeutics Inc | Carcinoma, Non-Small-Cell Lung | Details |
| Anti-CD3 x Anti-EGFR Bispecific Antibody (EGFRBi) Armed Fresh Peripheral Blood Mononuclear Cells therapy(University Of Virginia) | Phase 2 Clinical | University Of Virginia | Pancreatic Neoplasms | Details | |
| WSD-0922-FU | WSD0922-FU; WSD-0922-FU | Phase 2 Clinical | Wayshine Biopharm International Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| Neratinib (Fukang (Shanghai) Health Technology) | CVL009; CVL-009 | Phase 2 Clinical | Fukang (Shanghai) Health Technology Co Ltd | Solid tumours; Uterine Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| PRO-1286 | PRO-1286; GEN1286; GEN-1286 | Phase 2 Clinical | ProfoundBio (Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
| TRX-221 | TRX-221 | Phase 2 Clinical | Therapex Corp | Carcinoma, Non-Small-Cell Lung | Details |
| PH-009-1 | PH-009-1; PH009-1 | Phase 2 Clinical | Suzhou Puhe Pharmaceutical Technology Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| E-EDV-D682 | PNU-15982; E-EDV-D682; EGFR-EDV-PNU-15982 | Phase 2 Clinical | Engeneic Ltd | Pancreatic Neoplasms | Details |
| IBI334 | IBI334; IBI-334 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
| SHR-9839 | SHR-9839; SHR9839 | Phase 2 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Solid tumours; Colorectal Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
| DF9001 | DF-9001 | Phase 2 Clinical | Dragonfly Therapeutics Llc | Solid tumours | Details |
| DWP-708 | DWP-708 | Phase 2 Clinical | Daewoong Pharmaceutical Co Ltd | Acneiform Eruptions | Details |
| BBT-207 | BBT-207 | Phase 2 Clinical | Bridge Biotherapeutics Inc | Carcinoma, Non-Small-Cell Lung | Details |
| H-002 | H-002 | Phase 2 Clinical | Nanjing Hongyun Biological Technology Co Ltd | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| DAJH-1050766 | DAJH1050766; DAJH-1050766 | Phase 2 Clinical | Chengdu Diao Jiuhong Pharmaceutical Factory | Carcinoma, Non-Small-Cell Lung | Details |
| Anti-CTLA-4/PD-1 expressing EGFR-CAR-T | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Solid tumours | Details | |
| Anti-EGFR CAR-T cell therapy (Beijing Pregene) | Phase 2 Clinical | Colorectal Neoplasms | Details | ||
| HS-10375 | HS-10375 | Phase 2 Clinical | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| SMET-12 | SMET-12 | Phase 2 Clinical | Zhejiang Shimai Pharmaceutical Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
| EO-1001 | NT-113; APL-122 | Phase 2 Clinical | Edison Pharmaceuticals Inc | Neoplasms | Details |
| TAK-186 | EGFR x CD3 COBRA; MVC-101; TAK-186 | Phase 2 Clinical | Takeda Pharmaceutical Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| AP-L1898 | JS111; WJ-002; AP-L1898 | Phase 2 Clinical | Wigen Biomedicine technology (Shanghai) Co Ltd | Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| BPI-361175 | BPI-361175 | Phase 2 Clinical | Betta Pharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| CKD-702 | Phase 2 Clinical | Chong Kun Dang Pharmaceutical Corp | Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| REGN-7075 | REGN-7075 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
| JRF-103 | JRF103; JRF-103 | Phase 2 Clinical | Shenzhen Jinrui Foundation Biotechnology Co Ltd | Solid tumours | Details |
| Anti-EGFR-IL-dox (Swiss Group for Clinical Cancer Research) | Phase 2 Clinical | Schweizerische Arbeitsgemeinschaft Für Klinische Krebsforschung | Breast Neoplasms | Details | |
| Epertinib | S-222611 | Phase 2 Clinical | Shionogi & Co Ltd | Neoplasms | Details |
| Pirotinib Hydrochloride | KBP-5209 | Phase 2 Clinical | Shandong Xuanzhu Pharmaceutical Technology Co Ltd | Solid tumours; Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Humanized anti-EGFR monoclonal antibody (Hualan Biological Engineering/Henan shengming biotechnology) | Phase 2 Clinical | Henan Shengming Biotechnology Research Institute Co Ltd, Hualan Genetic Engineering Co Ltd | Colorectal Neoplasms | Details | |
| Anti-CD3/anti-EGFR -activated T cells (Barbara Ann Karmanos Cancer Institute) | Phase 2 Clinical | Barbara Ann Karmanos Cancer Institute, University Of Virginia | Glioblastoma; Pancreatic Neoplasms | Details | |
| Ascorbic Acid/Menadione | Phase 2 Clinical | Ic-Medtech Co, Summa Health System | Joint Diseases; Prostatic Neoplasms | Details | |
| Cetuximab biosimilar (Guilin Sanjin) | CDP-1; BC-001 | Phase 1 Clinical | Dragonboat Biopharmaceutical, Guilin Sanjin Pharmaceutical Co Ltd | Solid tumours; Neoplasms; Colorectal Neoplasms | Details |
| TQB3804 | TQB-3804 | Phase 1 Clinical | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| D2C7-IT | D2C7-(scdsFv)-PE38 KDEL; scds-D2C7 -PE38KDEL; D2C7-Immunotoxin; D2C7-IT | Phase 1 Clinical | Istari Oncology Inc, Duke University | Glioblastoma; Glioma | Details |
| SC-CAR4BRAIN | Phase 1 Clinical | Seattle Children'S Hospital | Sarcoma, Synovial; Neoplasms, Germ Cell and Embryonal; Diffuse Intrinsic Pontine Glioma; Sarcoma, Clear Cell; Osteosarcoma; Retinoblastoma; Neuroblastoma; Neurofibrosarcoma; Sarcoma, Ewing; Sarcoma; Solid tumours; Central Nervous System Neoplasms; Wilms Tumor; Carcinoma; Rhabdoid Tumor; Hepatoblastoma; Diffuse midline glioma; Desmoplastic Small Round Cell Tumor; Rhabdomyosarcoma | Details | |
| BPI-15086 | BPI-15086; BPI-15000 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| Recombinant anti-human EGFR antibody/IL-10 bispecific Fc fusion protein(Dingfu Biotarget) | CmAb-(IL10)2; DF203; DF-203 | Phase 1 Clinical | Dingfu Biotarget Co Ltd | Solid tumours | Details |
| MP-0274 | DARPin-41; SPA-28; CME-114; CME-115; CME-118; CME-119; MP-0274 | Phase 1 Clinical | Molecular Partners Ag | Neoplasms | Details |
| SYN-004 (Synermore Biologics) | LR-004; SYN-004 | Phase 1 Clinical | Lonn Ryonn Pharma Ltd, Synermore Biologics (Suzhou) Co Ltd | Solid tumours; Carcinoma; Lymphoma, Large B-Cell, Diffuse; Colorectal Neoplasms | Details |
| KY-1701 | KY-1701 | Phase 1 Clinical | Jiangsu Kanion Pharmaceutical Co Ltd | Breast Neoplasms | Details |
| Simotinib Hydrochloride | AL-6802; SIM-6802 | Phase 1 Clinical | Jiangsu Simcere Pharmaceutical Co Ltd, Advenchen Laboratories Llc | Carcinoma, Non-Small-Cell Lung | Details |
| Double-deleted Vaccinia Virus Plus CD/ SMR | JX-929; vvDD-CDSR | Phase 1 Clinical | Sillajen Inc | Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma | Details |
| TQ-B3395 | TQ-B3395; CT-1495; TQ-B-3395 | Phase 1 Clinical | Beijing Centaurus Biopharma Co Ltd | Neoplasms; Breast Neoplasms | Details |
| Cetuximab biosimilar (Shanghai Henlius Biotech) | HLX-05; JZB-29; JZB-28 | Phase 1 Clinical | Shanghai Henlius Biotech Inc | Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms | Details |
| Recombinant chimeric anti-EGFR monoclonal antibody (Zhejiang Xinwei Shengke Biotechnology) | Phase 1 Clinical | Zhejiang Xinweishengke Biotechnology Co Ltd | Esophageal Neoplasms | Details | |
| Anti-EGFR-bispecific antibody armed activated T-cell therapy (Memorial Sloan Kettering Cancer Center) | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Pancreatic Neoplasms | Details | |
| [89Zr]Panitumumab | Phase 1 Clinical | Vanderbilt-Ingram Cancer Center, University Of Alabama At Birmingham, Stanford University | Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Colonic Neoplasms | Details | |
| Recombinant chimeric anti-EGFR monoclonal antibody (Qilu Pharmaceutical) | QL-1105 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours | Details |
| EGFRvIII-CAR | Phase 1 Clinical | Duke University Medical Center | Glioblastoma | Details | |
| 14C-labeled poziotinib | Phase 1 Clinical | Spectrum Pharmaceuticals | Solid tumours | Details | |
| Puvitinib | Phase 1 Clinical | Suzhou Teligene Ltd | Solid tumours | Details | |
| Betatinib | TL-512 | Phase 1 Clinical | Aspedia Llc, Suzhou Teligene Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| KSP-QRH-E3-IRDye800 | Phase 1 Clinical | University Of Michigan | Cholangiocarcinoma | Details | |
| Hemay-020 | Hemay-020 | Phase 1 Clinical | Tianjin Hemay Pharmaceutical Co Ltd, Hainan General Sanyang Pharmaceutical Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
| Erlotinib gel (Sol-Gel Technologies) | SGT-210 | Phase 1 Clinical | Sol Gel Technologies Pte Ltd | Keratosis | Details |
| ZN-e4 | ZN-e4; KP-673 | Phase 1 Clinical | Zentalis Pharmaceuticals LLC, Zeno Pharma | Carcinoma, Non-Small-Cell Lung | Details |
| LY-01010 | LY-01010 | Phase 1 Clinical | Luye Pharma Group Ltd | Breast Neoplasms | Details |
| PB-357 | PB-357 | Phase 1 Clinical | Pfizer Inc | Neoplasms | Details |
| ZSP-0391 | ZSP-0391 | Phase 1 Clinical | Wuxi Apptec Co Ltd, Guangdong Zhongsheng Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| Neptinib Di-P-methylbenzenesulfonate | Phase 1 Clinical | Shenzhen Neptunus Pharmaceutical Research Institute Co Ltd | Stomach Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| QRH-882260 | QRH-882260 | Phase 1 Clinical | University Of Michigan | Cholangiocarcinoma | Details |
| Serclutamab talirine | ABBV-321 | Phase 1 Clinical | Abbvie Inc | Solid tumours | Details |
| Recombinant anti-EGFR chimeric antibody (Harbin Pharmaceutical) | Phase 1 Clinical | Harbin Pharmaceutical Group Holding Co Ltd | Colorectal Neoplasms | Details | |
| recombinant EGF/CRM-197 vaccine (Shanghai Humantech Biotechnology) | Phase 1 Clinical | Shanghai Humantech Biotechnology Co Ltd | Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| anti-EGFRvIII CAR T-cell therapy (Beijing Marino) | Phase 1 Clinical | Beijing Marino Biotechnology Co Ltd | Glioblastoma | Details | |
| naputinib tosilate (Shenzhen Neptunus Bioengineering) | NEP-015 | Phase 1 Clinical | Shenzhen Neptunus Bioengineering Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
| CXCR5 modified EGFR chimeric antigen receptor autologous T cells therapy | Phase 1 Clinical | Guangzhou Bio-Gene Technology Co Ltd | Carcinoma, Non-Small-Cell Lung | Details | |
| Diakine-DK2 10 (EGFR) | DK210; DK-2-10 | Phase 1 Clinical | Deka Biosciences Inc | Kidney Neoplasms; Solid tumours; Head and Neck Neoplasms; Carcinoma, Renal Cell; Pancreatic Neoplasms; Skin Neoplasms; Neoplasms; Genital Neoplasms, Female; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| HLX-42 | HLX-42; HLX42 | Phase 1 Clinical | Hanlin Biotechnology Co Ltd | Solid tumours; Neoplasms | Details |
| CMAB-017 | CMAB-017 | Phase 1 Clinical | Taizhou Mabtech Pharmaceutical Co Ltd | Solid tumours | Details |
| JY-016 | JY-016 | Phase 1 Clinical | Beijing Jingyitaixiang Technology Development Co Ltd, Beijing Eastern Biotech Co Ltd | Solid tumours; Colorectal Neoplasms; Lung Neoplasms | Details |
| PF-08046052 | SGN-EGFRd2; LAVA-1223 | Phase 1 Clinical | Vu University Medical Center, Lava Therapeutics NV, Seagen Inc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung | Details |
| CM-93 | CM-93 | Phase 1 Clinical | Shanghai Crimson Pharmaceutical Co Ltd | Glioblastoma | Details |
| BLU-701 | BLU-701; BLU 701 | Phase 1 Clinical | Blueprint Medicines Corp | Carcinoma, Bronchogenic; Bronchial Neoplasms; Thoracic Neoplasms; Carcinoma; Respiratory Tract Diseases; Neoplasms; Lung Diseases; Respiratory Tract Neoplasms; Neoplasms, Nerve Tissue; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
| CX-904 | CX-904 | Phase 1 Clinical | Amgen Inc, Cytomx Therapeutics Inc | Solid tumours; Neoplasms | Details |
| Cetuximab biosimilar (Humanwell Healthcare) | Phase 1 Clinical | Humanwell Healthcare (Group) Co Ltd | Colorectal Neoplasms | Details | |
| JS-212 | JS212; JS-212 | Phase 1 Clinical | Shanghai Junshi Biosciences Co Ltd | Solid tumours | Details |
| ALK-202 | ALK-202; ALK202 | Phase 1 Clinical | Shanghai Allink Biotherapeutics Co Ltd | Solid tumours; Neoplasm Metastasis | Details |
| Panitumumab biosimilar(Generium) | GNR-107 | Phase 1 Clinical | Generium Pharmaceuticals | Colorectal Neoplasms | Details |
| Sirotinib Maleate | XZP-5491 | Phase 1 Clinical | Shandong Xuanzhu Pharmaceutical Technology Co Ltd | Stomach Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung | Details |
| BG-60366 | BG-60366 | Phase 1 Clinical | BeOne Medicines Ltd | Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Tomuzotuximab | GT-MAB-5.2-GEX | Phase 1 Clinical | Glycotope Gmbh | Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| SAR-446368 | AMX-525; SAR446368; SAR-446368; VIR-5525 | Phase 1 Clinical | Amunix Pharmaceuticals Inc | Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| DWP709 | DWP709; DWP-818-1 | Phase 1 Clinical | Daewoong Pharmaceutical Co Ltd | Epidermolysis Bullosa | Details |
| CMDE-005 | CMDE-005; CMDE005; CMD-E005 | Phase 1 Clinical | Zhejiang Shimai Pharmaceutical Co Ltd | Solid tumours | Details |
| BG-T187 | BG-T187; BGT187 | Phase 1 Clinical | BeOne Medicines Ltd | Solid tumours; Lung Neoplasms; Gastrointestinal Neoplasms | Details |
| KY-0301 | KY-0301 | Phase 1 Clinical | Novatim Immune Therapeutics (Zhejiang) Co Ltd | Solid tumours | Details |
| IBI-3001 | IBI-3001; IBI3001 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
| BL-B16D1 | BLB16D1; BL-B16D1 | Phase 1 Clinical | Baili-Bio (Chengdu) Pharmaceutical Co Ltd, Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Breast Neoplasms | Details |
| HJ-002-03 | HJ-002-03; HJ00203 | Phase 1 Clinical | Jing Medicine Technology (Shanghai) Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| YL-221 | YL221; YL-221 | Phase 1 Clinical | MediLink Therapeutics Co Ltd | Solid tumours | Details |
| HS-10504 | HS10504; HS-10504 | Phase 1 Clinical | Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| BPI-520105 | BPI-520105; BPI520105 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours | Details |
| [14C]-PLB1004 | [14C]-PLB1004 | Phase 1 Clinical | Carcinoma, Non-Small-Cell Lung | Details | |
| FPI-2107 | [111In]-FPI-2107 | Phase 1 Clinical | Fusion Pharmaceuticals Inc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung | Details |
| FPI-2053 | FPI-2053 | Phase 1 Clinical | Fusion Pharmaceuticals Inc, Astrazeneca Plc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung | Details |
| KK-2260 | KK2260; KK-2260 | Phase 1 Clinical | Kyowa Kirin Co Ltd | Solid tumours; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details |
| TQB-2922 | TQB2922; TQB-2922 | Phase 1 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Neoplasms | Details |
| DM-005 | DM005; YH013; DM-005 | Phase 1 Clinical | Doma Biopharmaceutical (Suzhou) Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung | Details |
| FPI-2068 | [225Ac]-FPI-2068; FPI-2068 | Phase 1 Clinical | Fusion Pharmaceuticals Inc, Astrazeneca Plc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung | Details |
| KY-1702 | KY-1702; KY1702 | Phase 1 Clinical | Jiangsu Kanion Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| SNC-109 | SNC109; SNC-109 | Phase 1 Clinical | Shanghai Simnova Biotechnology Co Ltd | Glioblastoma | Details |
| HSK-40118 | HSK40118; HSK-40118 | Phase 1 Clinical | Haisco Pharmaceutical Group Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| AZD9592 | AZD-9592; AZD9592 | Phase 1 Clinical | Astrazeneca Plc | Solid tumours; Head and Neck Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| JANX-008 | EGFR-TRACTr; JANX008; JANX-008 | Phase 1 Clinical | Janux Therapeutics Inc | Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung | Details |
| TAVO-412 | TAVO-412 | Phase 1 Clinical | Tavotek Biotherapeutics (Hong Kong) Ltd, Tuochuang Biotechnology (Jiangsu) Co Ltd | Solid tumours; Neoplasms | Details |
| NX-019 | NX-019 | Phase 1 Clinical | Nalo Therapeutics Inc | Neoplasms | Details |
| BCG-011 | DM-001; BCG-011 | Phase 1 Clinical | Biocytogen Pharmaceuticals (Beijing) Co Ltd | Solid tumours; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| QLH-11811 | QLH-11811; QLH11811 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| Losatuxizumab vedotin | ABBV-221; ABBV221 | Phase 1 Clinical | Abbvie Inc | Neoplasms | Details |
| EGFR/B7H3 CAR-T | EGFR/B7H3 CAR-T | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Triple Negative Breast Neoplasms; Lung Neoplasms | Details |
| DXC004A | DXC-004-A; DXC004A | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Head and Neck Neoplasms; Solid tumours; Lung Neoplasms | Details |
| BB-1705 | BB-1705 | Phase 1 Clinical | Bliss Biopharmaceutical (Hangzhou) Co Ltd | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
| CART-EGFR-IL13Ra2 | CART-EGFR-IL13Ra2; CAR-T-EGFR-IL-13-Ra-2 | Phase 1 Clinical | University Of Pennsylvania | Glioblastoma | Details |
| EGFR IL12 CART | Phase 1 Clinical | Colorectal Neoplasms | Details | ||
| ERAS-801 | ERAS-801; JGK-068S | Phase 1 Clinical | Regents Of The University Of California | Glioblastoma | Details |
| NIP-142 | NIP-142 | Phase 1 Clinical | National Institutes Of Pharmaceutical Research And Development Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| TAS-2940 | TAS-2940 | Phase 1 Clinical | Taiho Oncology Inc | Solid tumours; Glioblastoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| [111In] Panitumumab | Phase 1 Clinical | Stanford University | Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details | |
| BC-3448 | BC3448; BC-3448 | Phase 1 Clinical | Wuxi BioCity | Solid tumours | Details |
| ABBV-637 | ABBV-637 | Phase 1 Clinical | Abbvie Inc | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
| M-1231 | M-1231 | Phase 1 Clinical | Emd Serono Research & Development Institute Inc, Merck Serono | Solid tumours; Esophageal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| HLX-35 | HLX-35; BNA035 | Phase 1 Clinical | Shanghai Henlius Biologics Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
| WTS-004 | WTS-004 | Phase 1 Clinical | Hangzhou Wutong Tree Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| FCN-411 | FCN-411 | Phase 1 Clinical | Shanghai Fosun Pharmaceutical (Group) Co Ltd | Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| ES-072 | ES-072 | Phase 1 Clinical | Zhejiang Bosheng Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| ZZ-06 | ZZ-06 | Phase 1 Clinical | Changchun Intellicrown Pharmaceutical Co Ltd | Solid tumours | Details |
| ABY-029 | ABY-029 | Phase 1 Clinical | Dartmouth College, Affibody Ab, Li-Cor Bioscience | Head and Neck Neoplasms; Sarcoma; Glioma | Details |
| Lifirafenib | BeiGene-283; BGB-283 | Phase 1 Clinical | BeOne Medicines Ltd | Solid tumours | Details |
| Cetuximab biosimilar (Enzene Biosciences) | Clinical | Enzene Biosciences Ltd | Carcinoma, Squamous Cell | Details | |
| VRN-11 | VRN11 | Clinical | Voronoi Inc | Carcinoma, Non-Small-Cell Lung | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Osimertinib Mesylate | AZD-9291; RDL94R2A16; AZD-9291 Mesylate; AZD9291 | Approved | Astrazeneca Plc | Tagrisso, 泰瑞沙 | United States | Carcinoma, Non-Small-Cell Lung | Astrazeneca Pharmaceutical Co Ltd | 2015-11-13 | Uterine Neoplasms; Multiple Myeloma; Breast Neoplasms; Prostatic Neoplasms; Meningeal Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Brain metastases; Endometrial Neoplasms; Urinary Bladder Neoplasms; Thyroid Neoplasms; Carcinoma, Squamous Cell; Lymphoma; Glioma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Melanoma; Uterine Cervical Neoplasms; Squamous Cell Carcinoma of Head and Neck; Head and Neck Neoplasms; Liver Neoplasms; Ovarian Neoplasms; Neoplasm, Residual; Hematologic Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Rectal Neoplasms; Solid tumours; Stomach Neoplasms; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Adenocarcinoma of Lung; Skin Neoplasms; Glioblastoma; Neoplasms | Details |
| Menadione | Approved | Eli Lilly And Company | Kyrbax | United States | null | Vitamin K Deficiency Bleeding; Hypoprothrombinemias; Exanthema | Details | |||
| PX-070101 | PX-070101 | Approved | Praxis Pharmaceuticals | Colombia | Diabetic Foot | Praxis Pharmaceuticals | 2015-07-01 | Diabetic Foot | Details | |
| Cetuximab biosimilar (Shanghai Zhangjiang Biotechnology) | STI-001; CMAB-009 | Approved | Shanghai Zhangjiang Biotechnology Co Ltd | Enlituo | Mainland China | Colorectal Neoplasms | Taizhou Mabtech Pharmaceutical Co Ltd | 2024-06-18 | Neoplasms; Colorectal Neoplasms | Details |
| Cetuximab sarotalocan | RM-1929; ASP-1929 | Approved | Aspyrian Therapeutics | Akalux | Japan | Head and Neck Neoplasms | Rakuten Medical Inc | 2020-09-25 | Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details |
| Cetuximab | IMC-C255; BMS-564717; EMD-271786; C-255; GT-MAB-5.2; ch-225; LY-2939777; NSC-714692 | Approved | Bristol-Myers Squibb Company, Eli Lilly And Company, Merck Serono | 爱必妥, Erbitux | United States | Colorectal Neoplasms | Imclone Gmbh | 2004-02-12 | Adenocarcinoma, Mucinous; Sarcoma; Oropharyngeal Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Carcinoma, Mucoepidermoid; Neuralgia; Endometrial Neoplasms; Lung Neoplasms; Fallopian Tube Neoplasms; Laryngeal Neoplasms; Carcinoma, Squamous Cell; Glioma; Nasopharyngeal Carcinoma; Esophageal Squamous Cell Carcinoma; Paranasal Sinus Neoplasms; Mouth Neoplasms; Lip Neoplasms; Precancerous Conditions; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Tongue Neoplasms; Complex Regional Pain Syndromes; Nose Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Liver Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esthesioneuroblastoma, Olfactory; Carcinoma, Basal Cell; Granuloma, Lethal Midline; Pancreatic Neoplasms; Neoplastic Cells, Circulating; Hypopharyngeal Neoplasms; Colonic Neoplasms; Neoplasms; Neoplasms, Squamous Cell; Glioblastoma; Carcinoma, Verrucous; Salivary Gland Neoplasms; N | Details |
| Afatinib Dimaleate | BIBW-2992-MA2; BIBW-2992 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Gilotrif, Giotrif, Tovok, 吉泰瑞, Tomtovok | United States | Carcinoma, Non-Small-Cell Lung | C.H. Boehringer Sohn Ag & Co. Kg | 2013-07-12 | Glioma; Prostatic Neoplasms; Brain Neoplasms; Urethral Neoplasms; Urologic Neoplasms; Colorectal Neoplasms; Ureteral Neoplasms; Lung Neoplasms; Carcinoma, Squamous Cell; Breast Neoplasms; Uterine Neoplasms; Esophageal Squamous Cell Carcinoma; Gallbladder Neoplasms; Lymphoma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Neoplasm Metastasis; Hematologic Neoplasms; Urinary Bladder Neoplasms; Multiple Myeloma; Liver Diseases; Chordoma; Neuroectodermal Tumors; Neoplasms, Squamous Cell; Glioblastoma; Neoplasms; Renal Insufficiency; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Rhabdomyosarcoma; Solid tumours; Head and Neck Neoplasms | Details |
| Epidermal growth factor biosimilar (RAS Lifesciences) | Approved | Ras Lifesciences | India | Ras Lifesciences | 2012-10-01 | Details | ||||
| Recombinant epidermal growth factor gel (Pavay Gene Pharmaceutical) | Approved | Guilin Huanuowei Gene Pharmaceutical Co Ltd | 易孚 | Mainland China | Skin Ulcer; Burns | Guilin Huanuowei Gene Pharmaceutical Co Ltd | 2002-12-23 | Skin Ulcer; Burns | Details | |
| Nimotuzumab | TheraCIMh-R3; YMB-1000; OSAG-10; KI-0502; KI-0501; DE-766; h-R3; OSAG-101; OSAG101 | Approved | Center Of Molecular Immunology, Cimym Biosciences | BIOMAb-EGFR, TheraCIM, 泰欣生, CIMAher, Theraloc, Taixinsheng | India | Head and Neck Neoplasms; Nasopharyngeal Neoplasms | null | 2006-07-21 | Nasopharyngeal Diseases; Carcinoma, Non-Small-Cell Lung; Esophageal Diseases; Uterine Cervical Neoplasms; Carcinoma, Squamous Cell; Glioma; Esophageal Squamous Cell Carcinoma; Colorectal Neoplasms; Nasopharyngeal Carcinoma; Neoplasms; Head and Neck Neoplasms; Nasopharyngeal Neoplasms; Pancreatic Neoplasms; Pancreatic neuroendocrine tumors (pNET); Anus Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Solid tumours | Details |
| Recombinant epidermal growth factor (Center for Genetic Engineering and Biotechnology/Praxis Pharmaceuticals) | Approved | Praxis Pharmaceuticals, Center For Genetic Engineering And Biotechnology | Heberprot-P | Cuba | Diabetic Foot | null | 2007-09-01 | Diabetic Foot | Details | |
| Erlotinib Hydrochloride | CP-358774-01; RO-0508231; NSC-718781; CP-358774; RG-1415; OSI-774; R-1415 | Approved | Genentech Inc | Tarceva, 特罗凯 | EU | Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung | Cheplapharm Registration GmbH | 2004-11-18 | Head and Neck Neoplasms; Leukemia, Promyelocytic, Acute; Solid tumours; Adenomatous Polyposis Coli; Kidney Neoplasms; Ependymoma; Liver Neoplasms; HIV Infections; Medulloblastoma; Brenner Tumor; Ovarian Neoplasms; Rhabdomyosarcoma; Neoplasm Recurrence, Local; Cystadenocarcinoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Rectal Neoplasms; Cystadenocarcinoma, Serous; Polycythemia Vera; Anus Neoplasms; Granuloma, Lethal Midline; Esthesioneuroblastoma, Olfactory; Carcinoma, Basal Cell; Cystadenocarcinoma, Mucinous; Pancreatic Neoplasms; Neoplasms; Salivary Gland Neoplasms; Myelodysplastic Syndromes; Colonic Neoplasms; Leukemia, Myelomonocytic, Chronic; Glioblastoma; Hypopharyngeal Neoplasms; Carcinoma, Verrucous; Nose Neoplasms; Nasopharyngeal Neoplasms; Carcinoma, Ovarian Epithelial; Adenocarcinoma of Lung; Leukemia, Myelomonocytic, Acute; Carcinoma, Transitional Cell; Liver Cirrhosis; Pachyonychia Congenita; Skin Neoplasms; Urinary Bladder Neoplasm | Details |
| Gefitinib | ZD-1839 | Approved | Astrazeneca Plc | 易瑞沙, Iressa | Japan | Carcinoma, Non-Small-Cell Lung | Astrazeneca Pharmaceutical Co Ltd | 2002-07-05 | Carcinoma, Mucoepidermoid; Lip Neoplasms; Mouth Neoplasms; Carcinoma, Squamous Cell; Glioma; Lung Neoplasms; Adenocarcinoma, Bronchiolo-Alveolar; Gliosarcoma; Astrocytoma; Oropharyngeal Neoplasms; Laryngeal Neoplasms; Colorectal Neoplasms; Gastrinoma; Carcinoma, Basosquamous; Brain Neoplasms; Medullary thyroid cancer (MTC); Nasopharyngeal Carcinoma; Prostatic Neoplasms; Urethral Neoplasms; Breast Neoplasms; Neoplasms, Germ Cell and Embryonal; Uterine Cervical Neoplasms; Gastrointestinal Neoplasms; Somatostatinoma; Carcinoma, Hepatocellular; Breast Neoplasms, Male; Tongue Neoplasms; Thyroid Cancer, Papillary; Laryngeal Diseases; Neoplasm Metastasis; Glucagonoma; Carcinoma, Non-Small-Cell Lung; Neoplasms, Neuroepithelial; Endometrial Neoplasms; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Paranasal Sinus Neoplasms; Brain metastases; Thyroid Neoplasms; Stomach Neoplasms; Glioblastoma; Vipoma; Carcinoma, Islet Cell; Insulinoma; Carcinoma, Basal Cell; Parathyroid Neoplasms; Granuloma, Lethal Midline; Squamo | Details |
| Brigatinib | AP-26113 | Approved | Ariad Pharmaceuticals Inc | Alunbrig, ALUNBRIG | United States | Carcinoma, Non-Small-Cell Lung | Takeda Pharmaceuticals USA Inc | 2017-04-28 | Solid tumours; Ependymoma; Carcinoma; Neoplasms; Neurofibromatosis 2; Myofibroma; Lymphoma, Large-Cell, Anaplastic; Granuloma, Plasma Cell; Lung Neoplasms; Brain metastases; Carcinoma, Non-Small-Cell Lung; Sarcoma, Kaposi; Neurilemmoma; Neuroma, Acoustic; Meningioma | Details |
| Recombinant Human Epidermal Growth Factor Derivative (Shenzhen Wastin Genetech) | rEGF | Approved | Shenzhen Watsin Genetech Ltd | 金因肽, GeneTime | Mainland China | Wounds and Injuries | Shenzhen Watsin Genetech Ltd | 2001-01-01 | Wounds and Injuries | Details |
| Nepidermin | DWP-401 | Approved | Daewoong Pharmaceutical Co Ltd | Easyef | South Korea | Alopecia; Diabetic Foot | Daewoong Pharmaceutical Co Ltd | 2001-01-01 | Diabetic Foot; Alopecia; Dry Eye Syndromes | Details |
| Icotinib Hydrochloride | BPI-2009H; BPI-2009C | Approved | Betta Pharmaceuticals Co Ltd | 凯美纳, Conmana | Mainland China | Carcinoma, Non-Small-Cell Lung | Betta Pharmaceuticals Co Ltd | 2011-06-07 | Solid tumours; Esophageal Neoplasms; Bronchial Neoplasms; Stomach Neoplasms; Adenocarcinoma of Lung; Neurofibromatosis 2; Psoriasis; Nasopharyngeal Carcinoma; Metastatic breast cancer; Lung Neoplasms; Carcinoma, Squamous Cell; Brain metastases; Carcinoma, Non-Small-Cell Lung; Neuroma, Acoustic; Adenocarcinoma | Details |
| Recombinant human EGF conjugated vaccine | Approved | Biotech Pharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung | Details | ||||||
| Recombinant epidermal growth factor (Bharat Biotech) | REGEN-D 60; REGEN-D 150 | Approved | Bharat Biotech International Ltd | India | Diabetic Foot; Burns | Bharat Biotech International Ltd | 2005-01-01 | Diabetic Foot; Burns | Details | |
| Lazertinib | JNJ-73841937; JNJ-1937; GNS-1480; YH-25448 | Approved | Oscotec Inc, Janssen Biotech Inc, Yuhan Corp | Leclaza, Lazcluze | South Korea | Carcinoma, Non-Small-Cell Lung | Yuhan Corp | 2021-01-18 | Hepatic Insufficiency; Carcinoma, Non-Small-Cell Lung | Details |
| Recombinant epidermal growth factor biosimilar (Elea) | r-hu-EGF | Approved | Elea | Argentina | Diabetic Foot; Burns | Elea | 2015-01-01 | Diabetic Foot; Burns | Details | |
| Recombinant Human Epidermal Growth Factor Derivative Eye Drops (Shenzhen Wastin Genetech) | Approved | Shenzhen Watsin Genetech Ltd | 金因舒, GeneSoft | Mainland China | Corneal Diseases | Shenzhen Watsin Genetech Ltd | 2004-01-21 | Corneal Diseases | Details | |
| Necitumumab | LY-3012211; IMC-11F8 | Approved | Eli Lilly And Company | Portrazza | United States | Carcinoma, Non-Small-Cell Lung | Eli Lilly And Co (Ireland) Ltd | 2015-11-24 | Solid tumours; Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
| Cetuximab N01 | KL-A140; KLA140; A-140; KL-140; KLA-140 | Approved | Sichuan Kelun Pharmaceutical Co Ltd | 达泰莱 | Mainland China | Colorectal Neoplasms | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | 2025-01-24 | Rectal Neoplasms; Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Adenocarcinoma | Details |
| Panitumumab | ABX-0303; E7.6.3; ABX-10221; AMG-954; ABX-EGF | Approved | Amgen Inc | Vectibix | United States | Colorectal Neoplasms | Amgen Inc | 2006-09-27 | Malignant Carcinoid Syndrome; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Exanthema; Neoplasm Metastasis; Glioma; Adenoma, Pleomorphic; Lung Neoplasms; Carcinoma, Squamous Cell; Colorectal Neoplasms; Brain Neoplasms; Prostatic Neoplasms; Head and Neck Neoplasms; Pancreatic Neoplasms; Salivary Gland Neoplasms; Neoplasms; Colonic Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Esophageal Neoplasms; Rectal Neoplasms; Kidney Neoplasms; Solid tumours | Details |
| Neratinib Maleate | CAN-030; PB-272; HKI-272; PF-0528767; WAY-179272 | Approved | Pfizer Inc | Nerlynx, 贺俪安, 汉奈佳 | United States | Breast Neoplasms | Puma Biotechnology Inc | 2017-07-17 | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Hepatic Insufficiency; Colorectal Neoplasms; Lung Neoplasms; Metastatic breast cancer; Brain metastases; Carcinoma, Non-Small-Cell Lung | Details |
| Cetuximab biosimilar (CinnaGen) | Approved | Cinnagen | Iran | Colorectal Neoplasms | Cinnagen | 2017-01-01 | Colorectal Neoplasms | Details | ||
| Lapatinib Ditosylate Hydrate | GW-572016; GW-572016F; GW-2016 | Approved | Glaxosmithkline Plc, Novartis Pharma Ag | Tykerb, Tyverb, 泰立沙, Tykerb/Tyverb | United States | Breast Neoplasms | Novartis Pharma Ag | 2007-03-13 | Lymphoma; Gliosarcoma; Bile Duct Neoplasms; Oropharyngeal Neoplasms; Carcinoma, Mucoepidermoid; Carcinoma, Acinar Cell; Brain metastases; Lung Neoplasms; Glioma; Gallbladder Neoplasms; Neoplasms, Gonadal Tissue; Carcinoma, Squamous Cell; Mouth Neoplasms; Lip Neoplasms; Endometrial Neoplasms; Astrocytoma; Paranasal Sinus Neoplasms; Laryngeal Neoplasms; Metastatic breast cancer; Uterine Cervical Neoplasms; Adenocarcinoma; Melanoma; Tongue Neoplasms; Breast Neoplasms, Male; Carcinoma, Hepatocellular; Neoplasm Metastasis; Laryngeal Diseases; Neuroma, Acoustic; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Carcinoma, Ovarian Epithelial; Liver Neoplasms; Ependymoma; Medulloblastoma; Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Abdominal Neoplasms; Carcinoma, Renal Cell; Carcinoma; Neoplasms; Salivary Gland Neoplasms; Glioblastoma; Head and Neck Neoplasms; Pancreatic Neoplasms; Carcinoma, Verrucous; Hypopharyngeal Neoplasms; Nose N | Details |
| Recombinant epidermal growth factor (Shanghai Haohai ) | Approved | Shanghai Haohai Biological Technology Co Ltd | 康合素 | Mainland China | Burns | Shanghai Haohai Biological Technology Co Ltd | 2001-01-01 | Burns | Details | |
| Amivantamab | JNJ-61186372; JNJ-372; JNJ-6372; CNTO4424; CNTO-4424 | Approved | Johnson & Johnson Innovative Medicine, Genmab A/S | RYBREVANT | United States | Carcinoma, Non-Small-Cell Lung | Janssen Biotech Inc | 2021-05-21 | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Glioblastoma; Carcinoma, Adenoid Cystic; Colorectal Neoplasms; Glioma; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Hepatocellular | Details |
| Recombinant epidermal growth factor drop (Pavay Gene Pharmaceutical) | Approved | Guilin Huanuowei Gene Pharmaceutical Co Ltd | 易贝 | Mainland China | Corneal Diseases | Guilin Huanuowei Gene Pharmaceutical Co Ltd | 2002-04-12 | Corneal Diseases; Xerophthalmia | Details | |
| Pyrotinib Maleate | BLTN; HTI-1001; SHR-1258 | Approved | Jiangsu Hengrui Medicine Co Ltd | 艾瑞妮 | Mainland China | Breast Neoplasms | Jiangsu Hengrui Medicine Co Ltd | 2018-08-12 | Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Adenocarcinoma of Lung; Neoplasms; Breast Neoplasms; Bile Duct Neoplasms; Metastatic breast cancer; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms | Details |
| Dacomitinib | PF-00299804-03; PF-00299804-3; PF-00299804; PF-299804; PF-299; PF-804 | Approved | Pfizer Inc | Vizimpro | United States | Carcinoma, Non-Small-Cell Lung | Pfizer Inc | 2018-09-27 | Colorectal Neoplasms; Adenocarcinoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Mouth Neoplasms; Lung Neoplasms; Carcinoma, Squamous Cell; Penile Neoplasms; Head and Neck Neoplasms; Brain Neoplasms; Liver Diseases; Carcinoma, Large Cell; Glioblastoma; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Solid tumours | Details |
| Mouse epidermal growth factor (Hangzhou Tianmushan Pharmaceutical) | Approved | Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd | 一夫 | Wounds and Injuries | Details |